Stockreport

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. - Common stock  (INMB) 
PDF BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatmen [Read more]